Current insights into matrix metalloproteinases and glioma progression: transcending the degradation boundary

References

• Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131(6):803–820.
   PubMed Web of Science ®Google Scholar
• Mansouri A, Karamchandani J, Das S. Molecular genetics of secondary glioblastoma. 2017. Available from: https://www.ncbi.nlm.nih.gov/books/NBK469981. Accessed July 18, 2018.
   Google Scholar
• van Meter T, Dumur C, Hafez N, Garrett C, Fillmore H, Broaddus WC. Microarray analysis of MRI-defined tissue samples in glioblastoma reveals differences in regional expression of therapeutic targets. Diagn Mol Pathol. 2006;15(4):195–205.
   Google Scholar
• Shergalis A, Bankhead A, Luesakul U, Muangsin N, Neamati N. Current challenges and opportunities in treating glioblastoma. Pharmacol Rev. 2018;70(3):412–445.
   PubMed Web of Science ®Google Scholar
• Pellerino A, Franchino F, Soffietti R, Rudà R. Overview on current treatment standards in high-grade gliomas. Q J Nucl Med Mol Imaging. Epub 2018 Apr 26.
   Google Scholar
• Fernandes C, Costa A, Osório L. Current Standards of Care in Glioblastoma Therapy. 2017. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29251860. Accessed May 25, 2018.
   Google Scholar
• Ostrom QT, Gittleman H, Liao P, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2010–2014. Neuro Oncol. 2017;19 Suppl 5:v1–v88.
   Google Scholar
• Jobin PG, Butler GS, Overall CM. New intracellular activities of matrix metalloproteinases shine in the moonlight. Biochim Biophys Acta. 2017;1864(11 Pt A):2043–2055.
   PubMed Web of Science ®Google Scholar
• Xie Y, Mustafa A, Yerzhan A, et al. Nuclear matrix metalloproteinases: functions resemble the evolution from the intracellular to the extracellular compartment. Cell Death Discov. 2017;3:17036.
   PubMed Web of Science ®Google Scholar
• Murphy G. Riding the metalloproteinase roller coaster. J Biol Chem. 2017;292(19):7708–7718.
   Web of Science ®Google Scholar
• Groves MD, Puduvalli VK, Conrad CA, et al. Phase II trial of temozolomide plus marimastat for recurrent anaplastic gliomas: a relationship among efficacy, joint toxicity and anticonvulsant status. J Neurooncol. 2006;80(1):83–90.
   Web of Science ®Google Scholar
• Brzdak P, Nowak D, Wiera G, Mozrzymas JW. Multifaceted roles of metzincins in CNS physiology and pathology: from synaptic plasticity and cognition to neurodegenerative disorders. Front Cell Neurosci. 2017;11:178.
   Web of Science ®Google Scholar
• Hagemann C, Anacker J, Ernestus RI, Vince GH. A complete compilation of matrix metalloproteinase expression in human malignant gliomas. World J Clin Oncol. 2012;3(5):67–79.
   PubMedGoogle Scholar
• Vanmeter TE, Rooprai HK, Kibble MM, Fillmore HL, Broaddus WC, Pilkington GJ. The role of matrix metalloproteinase genes in glioma invasion: co-dependent and interactive proteolysis. J Neurooncol. 2001;53(2):213–235.
   PubMed Web of Science ®Google Scholar
• Fillmore HL, Vanmeter TE, Broaddus WC. Membrane-type matrix metalloproteinases (MT-MMPs): expression and function during glioma invasion. J Neurooncol. 2001;53(2):187–202.
   PubMed Web of Science ®Google Scholar
• Fanjul-Fernández M, Folgueras AR, Cabrera S, López-Otín C. Matrix metalloproteinases: evolution, gene regulation and functional analysis in mouse models. Biochim Biophys Acta. 2010;1803(1):3–19.
   PubMed Web of Science ®Google Scholar
• Overall CM, López-Otín C. Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer. 2002;2(9):657–672.
   PubMed Web of Science ®Google Scholar
• Page-Mccaw A, Ewald AJ, Werb Z. Matrix metalloproteinases and the regulation of tissue remodelling. Nat Rev Mol Cell Biol. 2007;8(3):221–233.
   PubMed Web of Science ®Google Scholar
• Loffek S, Schilling O, Franzke CW. Biological role of matrix metalloproteinases: a critical balance. Eur Respir J. 2011;38(1):191–208.
   PubMed Web of Science ®Google Scholar
• Gaffney J, Solomonov I, Zehorai E, Sagi I. Multilevel regulation of matrix metalloproteinases in tissue homeostasis indicates their molecular specificity in vivo. Matrix Biol. 2015;44–46:191–199.
   Web of Science ®Google Scholar
• Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res. 2006;69(3):562–573.
   PubMed Web of Science ®Google Scholar
• Bode W, Maskos K. Structural studies on MMPs and TIMPs. Methods Mol Biol. 2001;151:45–77.
   PubMedGoogle Scholar
• Wells EM, Packer RJ. Pediatric brain tumors. Continuum (Minneap Minn). 2015;21(2):373–396.
   Google Scholar
• Mott JD, Werb Z. Regulation of matrix biology by matrix metalloproteinases. Curr Opin Cell Biol. 2004;16(5):558–564.
   PubMed Web of Science ®Google Scholar
• Mccawley LJ, Matrisian LM. Matrix metalloproteinases: they’re not just for matrix anymore! Curr Opin Cell Biol. 2001;13(5):534–540.
   PubMed Web of Science ®Google Scholar
• Chaudhary A, Singh M, Bharti AC, Asotra K, Sundaram S, Mehrotra R. Genetic polymorphisms of matrix metalloproteinases and their inhibitors in potentially malignant and malignant lesions of the head and neck. J Biomed Sci. 2010;17:10.
   PubMed Web of Science ®Google Scholar
• Kadoglou NP, Liapis CD. Matrix metalloproteinases: contribution to pathogenesis, diagnosis, surveillance and treatment of abdominal aortic aneurysms. Curr Med Res Opin. 2004;20(4):419–432.
   PubMed Web of Science ®Google Scholar
• Overall CM. Molecular determinants of metalloproteinase substrate specificity: matrix metalloproteinase substrate binding domains, modules, and exosites. Mol Biotechnol. 2002;22(1):51–86.
   PubMed Web of Science ®Google Scholar
• Fields GB. Interstitial collagen catabolism. J Biol Chem. 2013;288(13):8785–8793.
   Web of Science ®Google Scholar
• Crabbe T, Ioannou C, Docherty AJP. Human progelatinase A can be activated by autolysis at a rate that is concentration-dependent and enhanced by heparin bound to the C-terminal domain. Eur J Biochem. 1993;218(2):431–438.
   PubMedGoogle Scholar
• Dumin JA, Dickeson SK, Stricker TP, et al. Pro-collagenase-1 (matrix metalloproteinase-1) binds the α2β1 integrin upon release from keratinocytes migrating on type I collagen. J Biol Chem. 2001;276(31):29368–29374.
   Web of Science ®Google Scholar
• Itoh Y, Takamura A, Ito N, et al. Homophilic complex formation of MT1-MMP facilitates proMMP-2 activation on the cell surface and promotes tumor cell invasion. EMBO J. 2001;20(17):4782–4793.
   PubMed Web of Science ®Google Scholar
• Pei D, Kang T, Qi H. Cysteine array matrix metalloproteinase (CA-MMP)/MMP-23 is a type II transmembrane matrix metalloproteinase regulated by a single cleavage for both secretion and activation. J Biol Chem. 2000;275(43):33988–33997.
   PubMed Web of Science ®Google Scholar
• van Wart HE, Birkedal-Hansen H. The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. Proc Natl Acad Sci U S A. 1990;87(14):5578–5582.
   PubMed Web of Science ®Google Scholar
• Hadler-Olsen E, Fadnes B, Sylte I, Uhlin-Hansen L, Winberg JO. Regulation of matrix metalloproteinase activity in health and disease. FEBS J. 2011;278(1):28–45.
   PubMed Web of Science ®Google Scholar
• Ra HJ, Parks WC. Control of matrix metalloproteinase catalytic activity. Matrix Biol. 2007;26(8):587–596.
   PubMed Web of Science ®Google Scholar
• Prior SH, Fulcher YG, Koppisetti RK, Jurkevich A, van Doren SR. Charge-triggered membrane insertion of matrix metalloproteinase-7, supporter of innate immunity and tumors. Structure. 2015;23(11):2099–2110.
   Web of Science ®Google Scholar
• Murphy G, Nagase H. Localizing matrix metalloproteinase activities in the pericellular environment. FEBS J. 2011;278(1):2–15.
   PubMed Web of Science ®Google Scholar
• Brew K, Nagase H. The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity. Biochim Biophys Acta. 1803;2010(1):55–71.
   Google Scholar
• Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res. 2003;92(8):827–839.
   PubMed Web of Science ®Google Scholar
• Deshane J, Garner CC, Sontheimer H. Chlorotoxin inhibits glioma cell invasion via matrix metalloproteinase-2. J Biol Chem. 2003;278(6):4135–4144.
   PubMed Web of Science ®Google Scholar
• Nakano A, Tani E, Miyazaki K, Yamamoto Y, Furuyama J. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in human gliomas. J Neurosurg. 1995;83(2):298–307.
   Web of Science ®Google Scholar
• Lampert K, Machein U, Machein MR, Conca W, Peter HH, Volk B. Expression of matrix metalloproteinases and their tissue inhibitors in human brain tumors. Am J Pathol. 1998;153(2):429–437.
   Web of Science ®Google Scholar
• Kachra Z, Beaulieu E, Delbecchi L, et al. Expression of matrix metalloproteinases and their inhibitors in human brain tumors. Clin Exp Metastasis. 1999;17(7):555–566.
   Web of Science ®Google Scholar
• Pagenstecher A, Wussler EM, Opdenakker G, Volk B, Campbell IL. Distinct expression patterns and levels of enzymatic activity of matrix metalloproteinases and their inhibitors in primary brain tumors. J ­Neuropathol Exp Neurol. 2001;60(6):598–612.
   PubMed Web of Science ®Google Scholar
• Gabelloni P, da Pozzo E, Bendinelli S, et al. Inhibition of metalloproteinases derived from tumours: new insights in the treatment of human glioblastoma. Neuroscience. 2010;168(2):514–522.
   Web of Science ®Google Scholar
• Hagemann C, Anacker J, Haas S, et al. Comparative expression pattern of matrix-metalloproteinases in human glioblastoma cell-lines and primary cultures. BMC Res Notes. 2010;3:293.
   PubMedGoogle Scholar
• Hannocks MJ, Zhang X, Gerwien H, et al. The gelatinases, MMP-2 and MMP-9, as fine tuners of neuroinflammatory processes. Matrix Biol. Epub 2017 Nov 17.
   Google Scholar
• Rempe RG, Hartz AM, Bauer B. Matrix metalloproteinases in the brain and blood–brain barrier: versatile breakers and makers. J Cereb Blood Flow Metab. 2016;36(9):1481–1507.
   PubMed Web of Science ®Google Scholar
• Brkic M, Balusu S, Libert C, Vandenbroucke RE. Friends or foes: matrix metalloproteinases and their multifaceted roles in neurodegenerative diseases. Mediators Inflamm. 2015;2015:620581.
   PubMed Web of Science ®Google Scholar
• Warren KM, Reeves TM, Phillips LL. MT5-MMP, ADAM-10, and N-cadherin act in concert to facilitate synapse reorganization after traumatic brain injury. J Neurotrauma. 2012;29(10):1922–1940.
   PubMed Web of Science ®Google Scholar
• Yong VW, Agrawal SM, Stirling DP. Targeting MMPs in acute and chronic neurological conditions. Neurotherapeutics. 2007;4(4):580–589.
   Web of Science ®Google Scholar
• Pullen NA, Anand M, Cooper PS, Fillmore HL. Matrix metalloproteinase-1 expression enhances tumorigenicity as well as tumor-related angiogenesis and is inversely associated with TIMP-4 expression in a model of glioblastoma. J Neurooncol. 2012;106(3):461–471.
   Web of Science ®Google Scholar
• Ezhilarasan R, Jadhav U, Mohanam I, Rao JS, Gujrati M, Mohanam S. The hemopexin domain of MMP-9 inhibits angiogenesis and retards the growth of intracranial glioblastoma xenograft in nude mice. Int J Cancer. 2009;124(2):306–315.
   Web of Science ®Google Scholar
• Lakka SS, Gondi CS, Dinh DH, et al. Specific Interference of urokinase-type plasminogen activator receptor and matrix metalloproteinase-9 gene expression induced by double-stranded RNA results in decreased invasion, tumor growth, and angiogenesis in gliomas. J Biol Chem. 2005;280(23):21882–21892.
   Web of Science ®Google Scholar
• Ramnath N, Creaven PJ. Matrix metalloproteinase inhibitors. Curr Oncol Rep. 2004;6(2):96–102.
   Google Scholar
• Steward WP, Thomas AL. Marimastat: the clinical development of a matrix metalloproteinase inhibitor. Expert Opin Investig Drugs. 2000;9(12):2913–2922.
   Web of Science ®Google Scholar
• Butler GS, Overall CM. Updated biological roles for matrix metalloproteinases and new “intracellular” substrates revealed by degradomics. Biochemistry. 2009;48(46):10830–10845.
   PubMed Web of Science ®Google Scholar
• Gravendeel LA, Kouwenhoven MC, Gevaert O, et al. Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology. Cancer Res. 2009;69(23):9065–9072.
   PubMed Web of Science ®Google Scholar
• Ramachandran RK, Sørensen MD, Aaberg-Jessen C, Hermansen SK, Kristensen BW. Expression and prognostic impact of matrix metalloproteinase-2 (MMP-2) in astrocytomas. PLoS One. 2017;12(2):e0172234.
   Web of Science ®Google Scholar
• Anand M, van Meter TE, Fillmore HL. Epidermal growth factor induces matrix metalloproteinase-1 (MMP-1) expression and invasion in glioma cell lines via the MAPK pathway. J Neurooncol. 2011;104(3):679–687.
   Web of Science ®Google Scholar
• Thorns V, Walter GF, Thorns C. Expression of MMP-2, MMP-7, MMP-9, MMP-10 and MMP-11 in human astrocytic and oligodendroglial gliomas. Anticancer Res. 2003;23(5A):3937–3944.
   PubMed Web of Science ®Google Scholar
• Deryugina EI, Bourdon MA, Luo GX, Reisfeld RA, Strongin A. Matrix metalloproteinase-2 activation modulates glioma cell migration. J Cell Sci. 1997;110(Pt 1):2473–2482.
   Google Scholar
• Musumeci G, Magro G, Cardile V, et al. Characterization of matrix metalloproteinase-2 and -9, ADAM-10 and N-cadherin expression in human glioblastoma multiforme. Cell Tissue Res. 2015;362(1):45–60.
   PubMed Web of Science ®Google Scholar
• Komatsu K, Nakanishi Y, Nemoto N, Hori T, Sawada T, Kobayashi M. Expression and quantitative analysis of matrix metalloproteinase-2 and -9 in human gliomas. Brain Tumor Pathol. 2004;21(3):105–112.
   PubMedGoogle Scholar
• Jaworski DM. Developmental regulation of membrane type-5 matrix metalloproteinase (MT5-MMP) expression in the rat nervous system. Brain Res. 2000;860(1–2):174–177.
   Web of Science ®Google Scholar
• Hayashita-Kinoh H, Kinoh H, Okada A, et al. Membrane-type 5 matrix metalloproteinase is expressed in differentiated neurons and regulates axonal growth. Cell Growth Differ. 2001;12(11):573–580.
   Google Scholar
• Llano E, Pendás AM, Freije JP, et al. Identification and characterization of human MT5-MMP, a new membrane-bound activator of progelatinase A overexpressed in brain tumors. Cancer Res. 1999;59(11):2570–2576.
   PubMed Web of Science ®Google Scholar
• Ross HH, Fillmore HL. Identification of a novel human MT5-MMP transcript variant in multipotent NT2 cells. FEBS Lett. 2007;581(30):5923–5928.
   Web of Science ®Google Scholar
• Venkatesh HS, Tam LT, Woo PJ, et al. Targeting neuronal activity-regulated neuroligin-3 dependency in high-grade glioma. Nature. 2017;549(7673):533–537.
   PubMed Web of Science ®Google Scholar
• Ahir BK, Ozer H, Engelhard HH, Lakka SS. MicroRNAs in glioblastoma pathogenesis and therapy: a comprehensive review. Crit Rev Oncol Hematol. 2017;120:22–33.
   PubMed Web of Science ®Google Scholar
• Huang SW, Ali ND, Zhong L, Shi J. MicroRNAs as biomarkers for human glioblastoma: progress and potential. Acta Pharmacol Sin. Epub 2018 Feb 8.
   Google Scholar
• Qu K, Lin T, Pang Q, et al. Extracellular miRNA-21 as a novel biomarker in glioma: evidence from meta-analysis, clinical validation and experimental investigations. Oncotarget. 2016;7(23):33994–34010.
   PubMedGoogle Scholar
• Wang H, Xu T, Jiang Y, Yan Y, Qin R, Chen J. MicroRNAs in human glioblastoma: from bench to beside. Front Biosci (Landmark Ed). 2015;20:105–118.
   PubMed Web of Science ®Google Scholar
• Brower JV, Clark PA, Lyon W, Kuo JS. MicroRNAs in cancer: glioblastoma and glioblastoma cancer stem cells. Neurochem Int. 2014;77:68–77.
   Web of Science ®Google Scholar
• Akhtar N, Rasheed Z, Ramamurthy S, Anbazhagan AN, Voss FR, Haqqi TM. MicroRNA-27b regulates the expression of matrix metalloproteinase 13 in human osteoarthritis chondrocytes. Arthritis Rheum. 2010;62(5):1361–1371.
   PubMedGoogle Scholar
• Wang J, Song Y, Zhang Y, et al. Cardiomyocyte overexpression of miR-27b induces cardiac hypertrophy and dysfunction in mice. Cell Res. 2012;22(3):516–527.
   PubMed Web of Science ®Google Scholar
• Li HR, Cui Q, Dong ZY, Zhang JH, Li HQ, Zhao L. Downregulation of MIR-27b is involved in loss of type II collagen by directly targeting matrix metalloproteinase 13 (MMP13) in human intervertebral disc degeneration. Spine. 2016;41(3):E116–E123.
   PubMed Web of Science ®Google Scholar
• Li YF, Li SH, Liu Y, Luo YT. Long noncoding RNA CIR promotes chondrocyte extracellular matrix degradation in osteoarthritis by acting as a sponge for miR-27b. Cell Physiol Biochem. 2017;43(2):602–610.
   PubMedGoogle Scholar
• Pastuszak-Lewandoska D, Kordiak J, Czarnecka KH, et al. Expression analysis of three miRNAs, miR-26a, miR-29b and miR-519d, in relation to MMP-2 expression level in non-small cell lung cancer patients: a pilot study. Med Oncol. 2016;33(8):96.
   Web of Science ®Google Scholar
• Wang H, Zhu Y, Zhao M, et al. miRNA-29c suppresses lung cancer cell adhesion to extracellular matrix and metastasis by targeting integrin β1 and matrix metalloproteinase 2 (MMP2). PLoS One. 2013;8(8):e70192.
   PubMed Web of Science ®Google Scholar
• Wang H, Guan X, Tu Y, et al. MicroRNA-29b attenuates non-small cell lung cancer metastasis by targeting matrix metalloproteinase 2 and PTEN. J Exp Clin Cancer Res. 2015;34:59.
   Web of Science ®Google Scholar
• Tang W, Zhu Y, Gao J, et al. MicroRNA-29a promotes colorectal cancer metastasis by regulating matrix metalloproteinase 2 and E-cadherin via KLF4. Br J Cancer. 2014;110(2):450–458.
   PubMed Web of Science ®Google Scholar
• Lu L, Xue X, Lan J, et al. MicroRNA-29a upregulates MMP2 in oral squamous cell carcinoma to promote cancer invasion and anti-apoptosis. Biomed Pharmacother. 2014;68(1):13–19.
   PubMed Web of Science ®Google Scholar
• Jones JA, Stroud RE, O’Quinn EC, et al. Selective microRNA suppression in human thoracic aneurysms: relationship of miR-29a to aortic size and proteolytic induction. Circulation. 2011;4(6):605–613.
   Web of Science ®Google Scholar
• Kim JH, Jeon S, Shin BA. MicroRNA-29 family suppresses the invasion of HT1080 human fibrosarcoma cells by regulating matrix metalloproteinase 2 expression. Chonnam Med J. 2017;53(2):161–167.
   Google Scholar
• Bougnaud S, Golebiewska A, Oudin A, et al. Molecular crosstalk between tumour and brain parenchyma instructs histopathological features in glioblastoma. Oncotarget. 2016;7(22):31955–31971.
   Google Scholar
• Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT. Angiogenesis in brain tumours. Nat Rev Neurosci. 2007;8(8):610–622.
   PubMed Web of Science ®Google Scholar
• Claesson-Welsh L, Welsh M. VEGFA and tumour angiogenesis. J Intern Med. 2013;273(2):114–127.
   PubMed Web of Science ®Google Scholar
• Mahase S, Rattenni RN, Wesseling P, et al. Hypoxia-mediated mechanisms associated with antiangiogenic treatment resistance in glioblastomas. Am J Pathol. 2017;187(5):940–953.
   PubMed Web of Science ®Google Scholar
• Thompson EM, Frenkel EP, Neuwelt EA. The paradoxical effect of bevacizumab in the therapy of malignant gliomas. Neurology. 2011;76(1):87–93.
   PubMed Web of Science ®Google Scholar
• Chen C, Huang R, Maclean A, et al. Recurrent high-grade glioma treated with bevacizumab: prognostic value of MGMT methylation, EGFR status and pretreatment MRI in determining response and survival. J Neurooncol. 2013;115(2):267–276.
   PubMed Web of Science ®Google Scholar
• Flanigan PM, Aghi MK. Adaptation to antiangiogenic therapy in neurological tumors. Cell Mol Life Sci. 2015;72(16):3069–3082.
   Web of Science ®Google Scholar
• Maherally Z, Fillmore HL, Tan SL, et al. Real-time acquisition of transendothelial electrical resistance in an all-human, in vitro, 3-dimensional, blood–brain barrier model exemplifies tight-junction integrity. FASEB J. 2018;32(1):168–182.
   Web of Science ®Google Scholar
• Miner JH, Li C, Mudd JL, Go G, Sutherland AE. Compositional and structural requirements for laminin and basement membranes during mouse embryo implantation and gastrulation. Development. 2004;131(10):2247–2256.
   PubMed Web of Science ®Google Scholar
• Tilling T, Korte D, Hoheisel D, Galla HJ. Basement membrane proteins influence brain capillary endothelial barrier function in vitro. J Neurochem. 1998;71(3):1151–1157.
   PubMed Web of Science ®Google Scholar
• Zagzag D, Zhong H, Scalzitti JM, Laughner E, Simons JW, Semenza GL. Expression of hypoxia-inducible factor 1α in brain tumors: association with angiogenesis, invasion, and progression. Cancer. 2000;88(11):2606–2618.
   PubMed Web of Science ®Google Scholar
• Caspani EM, Crossley PH, Redondo-Garcia C, Martinez S. Glioblastoma: a pathogenic crosstalk between tumor cells and pericytes. PLoS One. 2014;9(7):e101402.
   PubMed Web of Science ®Google Scholar
• von Baumgarten L, Brucker D, Tirniceru A, et al. Bevacizumab has differential and dose-dependent effects on glioma blood vessels and tumor cells. Clin Cancer Res. 2011;17(19):6192–6205.
   PubMed Web of Science ®Google Scholar
• Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer. 2008;8(8):592–603.
   PubMed Web of Science ®Google Scholar
• Machein MR, Renninger S, Lima-Hahn E, Plate KH. Minor contribution of bone marrow-derived endothelial progenitors to the vascularization of murine gliomas. Brain Pathol. 2003;13(4):582–597.
   Web of Science ®Google Scholar
• Yue WY, Chen ZP. Does vasculogenic mimicry exist in astrocytoma? J Histochem Cytochem. 2005;53(8):997–1002.
   Web of Science ®Google Scholar
• Soda Y, Marumoto T, Friedmann-Morvinski D, et al. Transdifferentiation of glioblastoma cells into vascular endothelial cells. Proc Natl Acad Sci U S A. 2011;108(11):4274–4280.
   PubMed Web of Science ®Google Scholar
• Ricci-Vitiani L, Pallini R, Biffoni M, et al. Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature. 2010;468(7325):824–828.
   PubMed Web of Science ®Google Scholar
• Hardee ME, Zagzag D. Mechanisms of glioma-associated neovascularization. Am J Pathol. 2012;181(4):1126–1141.
   PubMed Web of Science ®Google Scholar
• Deryugina EI, Quigley JP. Tumor angiogenesis: MMP-mediated induction of intravasation- and metastasis-sustaining neovasculature. Matrix Biol. 2015;44–46:94–112.
   Web of Science ®Google Scholar
• Handsley MM, Edwards DR. Metalloproteinases and their inhibitors in tumor angiogenesis. Int J Cancer. 2005;115(6):849–860.
   PubMed Web of Science ®Google Scholar
• Rundhaug JE. Matrix metalloproteinases and angiogenesis. J Cell Mol Med. 2005;9(2):267–285.
   PubMed Web of Science ®Google Scholar
• Fang J, Shing Y, Wiederschain D, et al. Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model. Proc Natl Acad Sci U S A. 2000;97(8):3884–3889.
   Web of Science ®Google Scholar
• Bergers G, Brekken R, Mcmahon G, et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol. 2000;2(10):737–744.
   PubMed Web of Science ®Google Scholar
• Jadhav U, Chigurupati S, Lakka SS, Mohanam S. Inhibition of matrix metalloproteinase-9 reduces in vitro invasion and angiogenesis in human microvascular endothelial cells. Int J Oncol. 2004;25(5):1407–1414.
   PubMed Web of Science ®Google Scholar
• Webb AH, Gao BT, Goldsmith ZK, et al. Inhibition of MMP-2 and MMP-9 decreases cellular migration, and angiogenesis in in vitro models of retinoblastoma. BMC Cancer. 2017;17:434.
   PubMed Web of Science ®Google Scholar
• Chetty C, Lakka SS, Bhoopathi P, Kunigal S, Geiss R, Rao JS. Tissue inhibitor of metalloproteinase 3 suppresses tumor angiogenesis in matrix metalloproteinase 2-down-regulated lung cancer. Cancer Res. 2008;68(12):4736–4745.
   PubMed Web of Science ®Google Scholar
• Rojiani MV, Alidina J, Esposito N, Rojiani AM. Expression of MMP-2 correlates with increased angiogenesis in CNS metastasis of lung carcinoma. Int J Clin Exp Pathol. 2010;3(8):775–781.
   PubMed Web of Science ®Google Scholar
• Weng Y, Cai M, Zhu J, et al. Matrix metalloproteinase activity in early-stage lung cancer. Onkologie. 2013;36(5):256–259.
   Google Scholar
• Mehner C, Hockla A, Miller E, Ran S, Radisky DC, Radisky ES. Tumor cell-produced matrix metalloproteinase 9 (MMP-9) drives malignant progression and metastasis of basal-like triple negative breast cancer. Oncotarget. 2014;5(9):2736–2749.
   PubMedGoogle Scholar
• Belotti D, Calcagno C, Garofalo A, et al. Vascular endothelial growth factor stimulates organ-specific host matrix metalloproteinase-9 expression and ovarian cancer invasion. Mol Cancer Res. 2008;6(4):525–534.
   PubMed Web of Science ®Google Scholar
• Belotti D, Paganoni P, Manenti L, et al. Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation. Cancer Res. 2003;63(17):5224–5229.
   PubMed Web of Science ®Google Scholar
• Zheng H, Takahashi H, Murai Y, et al. Expressions of MMP-2, MMP-9 and VEGF are closely linked to growth, invasion, metastasis and angiogenesis of gastric carcinoma. Anticancer Res. 2006;26(5 A):3579–3583.
   Google Scholar
• Du R, Petritsch C, Lu K, et al. Matrix metalloproteinase-2 regulates vascular patterning and growth affecting tumor cell survival and invasion in GBM. Neuro Oncol. 2008;10(3):254–264.
   Web of Science ®Google Scholar
• Choe G, Park JK, Jouben-Steele L, et al. Active matrix metalloproteinase 9 expression is associated with primary glioblastoma subtype. Clin Cancer Res. 2002;8(9):2894–2901.
   PubMed Web of Science ®Google Scholar
• Munaut C, Noël A, Hougrand O, Foidart JM, Boniver J, Deprez M. Vascular endothelial growth factor expression correlates with matrix metalloproteinases MT1-MMP, MMP-2 and MMP-9 in human glioblastomas. Int J Cancer. 2003;106(6):848–855.
   Web of Science ®Google Scholar
• Kim SJ, Shin JY, Lee KD, et al. Galectin-3 Facilitates cell motility in gastric cancer by up-regulating protease-activated receptor-1 (PAR-1) and matrix metalloproteinase-1 (MMP-1). PLoS One. 2011;6(9):e25103.
   Web of Science ®Google Scholar
• Huo N, Ichikawa Y, Kamiyama M, et al. MMP-7 (matrilysin) accelerated growth of human umbilical vein endothelial cells. Cancer Lett. 2002;177(1):95–100.
   Web of Science ®Google Scholar
• Nishizuka I, Ichikawa Y, Ishikawa T, et al. Matrilysin stimulates DNA synthesis of cultured vascular endothelial cells and induces angiogenesis in vivo. Cancer Lett. 2001;173(2):175–182.
   Web of Science ®Google Scholar
• Chantrain CF, Shimada H, Jodele S, et al. Stromal matrix metalloproteinase-9 regulates the vascular architecture in neuroblastoma by promoting pericyte recruitment. Cancer Res. 2004;64(5):1675–1686.
   Web of Science ®Google Scholar
• Li J, Zhang YP, Kirsner RS. Angiogenesis in wound repair: angiogenic growth factors and the extracellular matrix. Microsc Res Tech. 2003;60(1):107–114.
   PubMed Web of Science ®Google Scholar
• Beck L, d’Amore PA. Vascular development: cellular and molecular regulation. FASEB J. 1997;11(5):365–373.
   PubMed Web of Science ®Google Scholar
• Xu J, Rodriguez D, Petitclerc E, et al. Proteolytic exposure of a cryptic site within collagen type IV is required for angiogenesis and tumor growth in vivo. J Cell Biol. 2001;154(5):1069–1080.
   PubMed Web of Science ®Google Scholar
• Silletti S, Kessler T, Goldberg J, Boger DL, Cheresh DA. Disruption of matrix metalloproteinase 2 binding to integrin αvβ3 by an organic molecule inhibits angiogenesis and tumor growth in vivo. Proc Natl Acad Sci U S A. 2001;98(1):119–124.
   PubMed Web of Science ®Google Scholar
• Herren B, Levkau B, Raines EW, Ross R. Cleavage of β-catenin and plakoglobin and shedding of VE-cadherin during endothelial apoptosis: evidence for a role for caspases and metalloproteinases. Mol Biol Cell. 1998;9(6):1589–1601.
   Web of Science ®Google Scholar
• Patterson BC, Sang QA. Angiostatin-converting enzyme activities of human matrilysin (MMP-7) and gelatinase B/type IV collagenase (MMP-9). J Biol Chem. 1997;272(46):28823–28825.
   PubMed Web of Science ®Google Scholar
• O’Reilly MS, Wiederschain D, Stetler-Stevenson WG, Folkman J, Moses MA. Regulation of angiostatin production by matrix metalloproteinase-2 in a model of concomitant resistance. J Biol Chem. 1999;274(41):29568–29571.
   PubMed Web of Science ®Google Scholar
• Pozzi A, Moberg PE, Miles LA, Wagner S, Soloway P, Gardner HA. Elevated matrix metalloprotease and angiostatin levels in integrin α1 knockout mice cause reduced tumor vascularization. Proc Natl Acad Sci U S A. 2000;97(5):2202–2207.
   PubMed Web of Science ®Google Scholar
• Pozzi A, Levine WF, Gardner HA. Low plasma levels of matrix metalloproteinase 9 permit increased tumor angiogenesis. Oncogene. 2002;21(2):272–281.
   Web of Science ®Google Scholar
• Ferreras M, Felbor U, Lenhard T, Olsen BR, Delaissé J-M. Generation and degradation of human endostatin proteins by various proteinases. FEBS Lett. 2000;486(3):247–251.
   PubMed Web of Science ®Google Scholar
• Sudhakar A, Sugimoto H, Yang C, Lively J, Zeisberg M, Kalluri R. Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by αvβ3 and α5β1 integrins. Proc Natl Acad Sci U S A. 2003;100(8):4766–4771.
   PubMed Web of Science ®Google Scholar
• Chantrain CF, Henriet P, Jodele S, et al. Mechanisms of pericyte recruitment in tumour angiogenesis: a new role for metalloproteinases. Eur J Cancer. 2006;42(3):310–318.
   Web of Science ®Google Scholar
• Absinta M, Ha SK, Nair G, et al. Human and nonhuman primate meninges harbor lymphatic vessels that can be visualized noninvasively by MRI. Elife. 2017;6:e29738.
   PubMed Web of Science ®Google Scholar
• Sowers JL, Johnson KM, Conrad C, Patterson JT, Sowers LC. The role of inflammation in brain cancer. Adv Exp Med Biol. 2014;816:75–105.
   PubMed Web of Science ®Google Scholar
• Benešová Y, Vašků A, Novotná H, et al. Matrix metalloproteinase-9 and matrix metalloproteinase-2 as biomarkers of various courses in multiple sclerosis. Mult Scler. 2009;15(3):316–322.
   Web of Science ®Google Scholar
• Avolio C, Ruggieri M, Giuliani F, et al. Serum MMP-2 and MMP-9 are elevated in different multiple sclerosis subtypes. J Neuroimmunol. 2003;136(1–2):46–53.
   PubMed Web of Science ®Google Scholar
• Waubant E, Goodkin D, Bostrom A, et al. IFN lowers MMP-9/TIMP-1 ratio, which predicts new enhancing lesions in patients with SPMS. Neurology. 2003;60(1):52–57.
   PubMed Web of Science ®Google Scholar
• Boz C, Ozmenoglu M, Velioglu S, et al. Matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in patients with relapsing–remitting multiple sclerosis treated with interferon beta. Clin Neurol Neurosurg. 2006;108(2):124–128.
   PubMed Web of Science ®Google Scholar
• Nakada M, Okada Y, Yamashita J. The role of matrix metalloproteinases in glioma invasion. Front Biosci. 2003;8(5):e261–e269.
   Google Scholar
• Abraham M, Shapiro S, Karni A, Weiner HL, Miller A. Gelatinases (MMP-2 and MMP-9) are preferentially expressed by Th1 vs. Th2 cells. J Neuroimmunol. 2005;163(1–2):157–164.
   Web of Science ®Google Scholar
• Yoshino et al. Effect of IFN-β on human glioma cell lines with temozolomide resistance. Int J Oncol. 2009;35(01):139–148.
   Google Scholar
• Wiranowska M, Rojiani AM, Gottschall PE, Moscinski LC, Johnson J, Saporta S. CD44 expression and MMP-2 secretion by mouse glioma cells: effect of interferon and anti-CD44 antibody. Anticancer Res. 2000;20(6B):4301–4306.
   Web of Science ®Google Scholar
• Mohsenzadegan M, Fayazi MR, Abdolmaleki M, Bakhshayesh M, Seif F, Mousavizadeh K. Direct immunomodulatory influence of IFN-β on human astrocytoma cells. Immunopharmacol Immunotoxicol. 2015;37(2):214–219.
   PubMed Web of Science ®Google Scholar
• Polukort SH, Rovatti J, Carlson L, et al. IL-10 enhances IgE-mediated mast cell responses and is essential for the development of experimental food allergy in IL-10-deficient mice. J Immunol. 2016;196(12):4865–4876.
   Web of Science ®Google Scholar
• Qayum AA, Paranjape A, Abebayehu D, et al. IL-10-induced miR-155 targets SOCS1 to enhance IgE-mediated mast cell function. J Immunol. 2016;196(11):4457–4467.
   Web of Science ®Google Scholar
• Wagner S, Stegen C, Bouterfa H, et al. Expression of matrix metalloproteinases in human glioma cell lines in the presence of IL-10. J Neurooncol. 1998;40(2):113–122.
   PubMed Web of Science ®Google Scholar
• Kawaji H, Tokuyama T, Yamasaki T, Amano S, Sakai N, Namba H. Interferon-β and temozolomide combination therapy for temozolomide monotherapy-refractory malignant gliomas. Mol Clin Oncol. 2015;3(4):909–913.
   Google Scholar
• Motomura K, Natsume A, Kishida Y, et al. Benefits of interferon-β and temozolomide combination therapy for newly diagnosed primary glioblastoma with the unmethylated MGMT promoter. Cancer. 2011;117(8):1721–1730.
   PubMed Web of Science ®Google Scholar
• Wolpert F, Happold C, Reifenberger G, et al. Interferon-β Modulates the Innate immune response against glioblastoma initiating cells. PLoS One. 2015;10(10):e0139603.
   PubMed Web of Science ®Google Scholar
• Cheng SM, Xing B, Li JC, Cheung BK, Lau AS. Interferon-γ regulation of TNFα-induced matrix metalloproteinase 3 expression and migration of human glioma T98G cells. Int J Cancer. 2007;121(6):1190–1196.
   Web of Science ®Google Scholar
• Qin H, Moellinger JD, Wells A, Windsor LJ, Sun Y, Benveniste EN. Transcriptional suppression of matrix metalloproteinase-2 gene expression in human astroglioma cells by TNF-α and IFN-γ. J Immunol. 1998;161(12):6664–6673.
   Web of Science ®Google Scholar
• Li R, Li G, Deng L, et al. IL-6 augments the invasiveness of U87MG human glioblastoma multiforme cells via up-regulation of MMP-2 and fascin-1. Oncol Rep. 2010;23(6):1553–1559.
   PubMed Web of Science ®Google Scholar
• Kesanakurti D, Chetty C, Dinh DH, Gujrati M, Rao JS. Role of MMP-2 in the regulation of IL-6/Stat3 survival signaling via interaction with α5β1 integrin in glioma. Oncogene. 2013;32(3):327–340.
   Web of Science ®Google Scholar
• Chen W, Xia T, Wang D, et al. Human astrocytes secrete IL-6 to promote glioma migration and invasion through upregulation of cytomembrane MMP14. Oncotarget. 2016;7(38):62425–62438.
   Google Scholar
• Markovic DS, Vinnakota K, Chirasani S, et al. Gliomas induce and exploit microglial MT1-MMP expression for tumor expansion. Proc Natl Acad Sci U S A. 2009;106(30):12530–12535.
   PubMed Web of Science ®Google Scholar
• Kudo M, Jono H, Shinriki S, et al. Antitumor effect of humanized anti-interleukin-6 receptor antibody (tocilizumab) on glioma cell proliferation. J Neurosurg. 2009;111(2):219–225.
   Web of Science ®Google Scholar
• Xue H, Yuan G, Guo X, et al. A novel tumor-promoting mechanism of IL6 and the therapeutic efficacy of tocilizumab: hypoxia-induced IL6 is a potent autophagy initiator in glioblastoma via the p-STAT3-MIR155-3p-CREBRF pathway. Autophagy. 2016;12(7):1129–1152.
   PubMed Web of Science ®Google Scholar
• Wang H, Lathia JD, Wu Q, et al. Targeting interleukin 6 signaling suppresses glioma stem cell survival and tumor growth. Stem Cells. 2009;27(10):2393–2404.
   PubMed Web of Science ®Google Scholar
• Roesch S, Rapp C, Dettling S, Herold-Mende C. When immune cells turn bad: tumor-associated microglia/macrophages in glioma. Int J Mol Sci. 2018;19(2):E436.
   PubMed Web of Science ®Google Scholar
• Hambardzumyan D, Gutmann DH, Kettenmann H. The role of microglia and macrophages in glioma maintenance and progression. Nat Neurosci. 2016;19(1):20–27.
   PubMed Web of Science ®Google Scholar
• Mangani D, Weller M, Sadr ES, et al. Limited role for transforming growth factor-β pathway activation-mediated escape from VEGF inhibition in murine glioma models. Neuro Oncol. 2016;18(12):1610–1621.
   PubMed Web of Science ®Google Scholar
• Miyauchi JT, Caponegro MD, Chen D, Choi MK, Li M, Tsirka SE. Deletion of neuropilin 1 from microglia or bone marrow-derived macrophages slows glioma progression. Cancer Res. 2018;78(3):685–694.
   Web of Science ®Google Scholar
• Delwar ZM, Kuo Y, Wen YH, Rennie PS, Jia W. Oncolytic virotherapy blockade by microglia and macrophages requires STAT1/3. Cancer Res. 2018;78(3):718–730.
   PubMed Web of Science ®Google Scholar
• Wang Y, Liu T, Yang N, Xu S, Li X, Wang D. Hypoxia and macrophages promote glioblastoma invasion by the CCL4-CCR5 axis. Oncol Rep. 2016;36(6):3522–3528.
   PubMed Web of Science ®Google Scholar
• Ellert-Miklaszewska A, Dabrowski M, Lipko M, Sliwa M, Maleszewska M, Kaminska B. Molecular definition of the pro-tumorigenic phenotype of glioma-activated microglia. Glia. 2013;61(7):1178–1190.
   PubMed Web of Science ®Google Scholar
• Vinnakota K, Hu F, Ku MC, et al. Toll-like receptor 2 mediates microglia/brain macrophage MT1-MMP expression and glioma expansion. Neuro Oncol. 2013;15(11):1457–1468.
   Web of Science ®Google Scholar
• Hu F, Ku MC, Markovic D, et al. Glioma-associated microglial MMP9 expression is upregulated by TLR2 signaling and sensitive to minocycline. Int J Cancer. 2014;135(11):2569–2578.
   Web of Science ®Google Scholar
• Hu F, a Dzaye OD, Hahn A, et al. Glioma-derived versican promotes tumor expansion via glioma-associated microglial/macrophages Toll-like receptor 2 signaling. Neuro Oncol. 2015;17(2):200–210.
   Web of Science ®Google Scholar
• Yi YJ, Huang SY, Chen L, Chen XR, Yang ZL, Ke YQ. Atorvastatin suppresses glioma invasion and migration by reducing microglial MT1-MMP expression. J Neuroimmunol. 2013;260(1–2):1–8.
   Web of Science ®Google Scholar
• Peng P, Wei W, Long C, Li J. Atorvastatin augments temozolomide’s efficacy in glioblastoma via prenylation-dependent inhibition of Ras signaling. Biochem Biophys Res Commun. 2017;489(3):293–298.
   Web of Science ®Google Scholar
• Bayat N, Ebrahimi-Barough S, Norouzi-Javidan A, et al. Anti-inflammatory effects of atorvastatin by suppressing TRAF3IP2 and IL-17RA in human glioblastoma spheroids cultured in a three-dimensional model: possible relevance to glioblastoma treatment. Mol Neurobiol. 2018;55(3):2102–2110.
   Web of Science ®Google Scholar
• Parajuli P, Anand R, Mandalaparty C, et al. Preferential expression of functional IL-17R in glioma stem cells: potential role in self-renewal. Oncotarget. 2016;7(5):6121–6135.
   Google Scholar
• Ye XZ, Xu SL, Xin YH, et al. Tumor-associated microglia/macrophages enhance the invasion of glioma stem-like cells via TGF-1 signaling pathway. J Immunol. 2012;189(1):444–453.
   PubMed Web of Science ®Google Scholar
• Skaper SD, Facci L, Zusso M, Giusti P. Neuroinflammation, mast cells, and glia: dangerous liaisons. Neuroscientist. 2017;23(5):478–498.
   Web of Science ®Google Scholar
• Vainchtein ID, Chin G, Cho FS, et al. Astrocyte-derived interleukin-33 promotes microglial synapse engulfment and neural circuit development. Science. 2018;359(6381):1269–1273.
   PubMed Web of Science ®Google Scholar
• Zhang J, Wang P, Ji W, Ding Y, Lu X. Overexpression of interleukin-33 is associated with poor prognosis of patients with glioma. Int J Neurosci. 2017;127(3):210–217.
   PubMed Web of Science ®Google Scholar
• Zhang JF, Wang P, Yan YJ, et al. IL-33 enhances glioma cell migration and invasion by upregulation of MMP2 and MMP9 via the ST2-NF-κB pathway. Oncol Rep. 2017;38(4):2033–2042.
   Web of Science ®Google Scholar
• Hsu CL, Neilsen CV, Bryce PJ. IL-33 Is produced by mast cells and regulates IgE-dependent inflammation. PLoS One. 2010;5(8):e11944.
   Google Scholar
• Wang JX, Kaieda S, Ameri S, et al. IL-33/ST2 axis promotes mast cell survival via BCLXL. Proc Natl Acad Sci U S A. 2014;111(28):10281–10286.
   Web of Science ®Google Scholar
• Joulia R, L’Faqihi FE, Valitutti S, Espinosa E. IL-33 fine tunes mast cell degranulation and chemokine production at the single-cell level. J Allergy Clin Immunol. 2017;140(2):497–509.
   PubMed Web of Science ®Google Scholar
• Wroblewski M, Bauer R, Córdova MC, et al. Mast cells decrease efficacy of anti-angiogenic therapy by secreting matrix-degrading granzyme B. Nat Commun. 2017;8(1):269.
   Google Scholar
• Roy A, Coum A, Marinescu VD, et al. Glioma-derived plasminogen activator inhibitor-1 (PAI-1) regulates the recruitment of LRP1 positive mast cells. Oncotarget. 2015;6(27):23647–23661.
   Google Scholar
• Põlajeva J, Sjösten AM, Lager N, et al. Mast cell accumulation in glioblastoma with a potential role for stem cell factor and chemokine CXCL12. PLoS One. 2011;6(9):e25222.
   Web of Science ®Google Scholar
• Attarha S, Roy A, Westermark B, Tchougounova E. Mast cells modulate proliferation, migration and stemness of glioma cells through downregulation of GSK3β expression and inhibition of STAT3 activation. Cell Signal. 2017;37:81–92.
   Web of Science ®Google Scholar
• Cwm O, Elkington PT, Brilha S, et al. Neutrophil-derived MMP-8 drives AMPK-dependent matrix destruction in human pulmonary tuberculosis. PLoS Pathog. 2015;11(5):e1004917.
   Web of Science ®Google Scholar
• Fossati G, Ricevuti G, Edwards SW, Walker C, Dalton A, Rossi ML. Neutrophil infiltration into human gliomas. Acta Neuropathol. 1999;98(4):349–354.
   PubMed Web of Science ®Google Scholar
• Zhang J, Zhang S, Song Y, et al. Prognostic role of neutrophil lymphocyte ratio in patients with glioma. Oncotarget. 2017;8(35):59217–59224.
   Google Scholar
• Hartmann P, Herholz K, Salzberger B, Petereit HF. Unusual and severe symptomatic impairment of neutrophil function after one cycle of temozolomide in patients with malignant glioma. Ann Hematol. 2004;83(4):212–217.
   Web of Science ®Google Scholar
• Graf MR, Prins RM, Merchant RE. IL-6 secretion by a rat T9 glioma clone induces a neutrophil-dependent antitumor response with resultant cellular, antiglioma immunity. J Immunol. 2001;166(1):121–129.
   PubMed Web of Science ®Google Scholar
• Fridlender ZG, Sun J, Kim S, et al. Polarization of tumor-associated neutrophil phenotype by TGF-β: “N1” versus “N2” TAN. Cancer Cell. 2009;16(3):183–194.
   PubMed Web of Science ®Google Scholar
• Uribe-Querol E, Rosales C. Neutrophils in cancer: two sides of the same coin. J Immunol Res. 2015;2015:983698.
   PubMed Web of Science ®Google Scholar
• Ostrand-Rosenberg S, Fenselau C. Myeloid-derived suppressor cells: immune-suppressive cells that impair antitumor immunity and are sculpted by their environment. J Immunol. 2018;200(2):422–431.
   PubMed Web of Science ®Google Scholar
• Xue J, Zhao Z, Zhang L, et al. Neutrophil-mediated anticancer drug delivery for suppression of postoperative malignant glioma recurrence. Nat Nanotechnol. 2017;12(7):692–700.
   PubMed Web of Science ®Google Scholar
• Brinkmann V, Reichard U, Goosmann C, et al. Neutrophil extracellular traps kill bacteria. Science. 2004;303(5663):1532–1535.
   PubMed Web of Science ®Google Scholar
• Carmona-Rivera C, Zhao W, Yalavarthi S, Kaplan MJ. Neutrophil extracellular traps induce endothelial dysfunction in systemic lupus erythematosus through the activation of matrix metalloproteinase-2. Ann Rheum Dis. 2015;74(7):1417–1424.
   Web of Science ®Google Scholar
• Huang Y, Rajappa P, Hu W, et al. A proangiogenic signaling axis in myeloid cells promotes malignant progression of glioma. J Clin Invest. 2017;127(5):1826–1838.
   PubMed Web of Science ®Google Scholar
• Reardon DA, Mitchell DA. The development of dendritic cell vaccine-based immunotherapies for glioblastoma. Semin Immunopathol. 2017;39(2):225–239.
   PubMed Web of Science ®Google Scholar
• Migliorini D, Dietrich PY, Stupp R, Linette GP, Posey AD, June CH. CAR T-cell therapies in glioblastoma: A first look. Clin Cancer Res. 2018;24(3):535–540.
   PubMed Web of Science ®Google Scholar
• Lang FF, Conrad C, Gomez-Manzano C, et al. Phase I study of DNX-2401 (delta-24-RGD) oncolytic adenovirus: replication and immunotherapeutic effects in recurrent malignant glioma. J Clin Oncol. 2018;36(14):1419–1427.
   PubMed Web of Science ®Google Scholar
• Gromeier M, Nair SK. Recombinant poliovirus for cancer immunotherapy. Annu Rev Med. 2018;69:289–299.
   PubMed Web of Science ®Google Scholar
• Zhu Z, Gorman MJ, Mckenzie LD, et al. Zika virus has oncolytic activity against glioblastoma stem cells. J Exp Med. 2017;214(10):2843–2857.
   PubMed Web of Science ®Google Scholar
• Mohanty S, Chen Z, Li K, et al. A novel theranostic strategy for MMP-14-expressing glioblastomas impacts survival. Mol Cancer Ther. 2017;16(9):1909–1921.
   PubMed Web of Science ®Google Scholar
• Daldrup-Link HE. Rethinking brain cancer therapy: tumor enzyme activatable theranostic nanoparticles. Mol Imaging. 2017;16:1536012117730950.
   Web of Science ®Google Scholar
• Barnes JM, Przybyla L, Weaver VM. Tissue mechanics regulate brain development, homeostasis and disease. J Cell Sci. 2017;130(1):71–82.
   PubMed Web of Science ®Google Scholar
• Jozic D, Bourenkov G, Lim NH, et al. X-ray structure of human proMMP-1: new insights into procollagenase activation and collagen binding. J Biol Chem. 2005;280(10):9578–9585.
   PubMed Web of Science ®Google Scholar